8. DEFINITIONS AND ACRONYMS This table of definitions and acronyms is specifically intended for interpretation of terms in relation to this policy and associated processes. Term Acronym Related terms Definition A harmful or serious reaction to immunoglobulin product administration requiring further treatment that should Adverse event be reported within the hospital and to the Therapeutic Administration (TGA), the Authoriser and Suppliers, as appropriate. Allocation of product to patients based on available domestic and imported immunoglobulin product, taking into Allocation account supply security reserve levels endorsed by governments to ensure sufficiency of supply Other clinical treatments that can be Alternative therapy Substitute therapy substituted for immunoglobulin therapy to a condition (i.e. plasma exchange). The council provides support to the COAG Health Council (CHC), by advising health ministers on strategic matters relating to the coordination of health services. Australian Health Ministers’ AHMAC AHMAC considers blood sector matters Advisory Council referred to it by the Jurisdictional Blood Committee (JBC) through the Hospitals Principle Committee, and reports as necessary to the CHC. The organisation that collects, processes Australian Red Blood and distributes and blood Blood Service Service components sourced from voluntary Australian blood donors. The process for assessing eligibility for access to immunoglobulin products Authorisation funded the national blood arrangements based on the Criteria. The point at which the patient is approved for initial qualifying or continuing immunoglobulin treatment. Patients will Authorisation date be authorised for a single dose or period of continuing treatment according to the Criteria.
8. DEFINITIONS AND ACRONYMS This table of definitions and acronyms is specifically intended for interpretation of terms in relation to this policy and associated processes. Term Acronym Related terms Definition Adverse event A harmful or serious reaction to immunoglobulin product administration requiring further treatment that should be reported within the hospital and to the Therapeutic Administration (TGA), the Authoriser and Suppliers, as appropriate. Allocation Allocation of product to patients based on available domestic and imported immunoglobulin product, taking into account supply security reserve levels endorsed by governments to ensure sufficiency of supply Alternative therapy Substitute therapy Other clinical treatments that can be substituted for immunoglobulin therapy to a condition (i.e. plasma exchange). Australian Health Ministers’ Advisory Council AHMAC The council provides support to the COAG Health Council (CHC), by advising health ministers on strategic matters relating to the coordination of health services. AHMAC considers blood sector matters referred to it by the Jurisdictional Blood Committee (JBC) through the Hospitals Principle Committee, and reports as necessary to the CHC. Australian Red Blood Service Blood Service The organisation that collects, processes and distributes and blood components sourced from voluntary Australian blood donors. Authorisation The process for assessing eligibility for access to immunoglobulin products funded the national blood arrangements based on the Criteria. Authorisation date The point at which the patient is approved for initial qualifying or continuing immunoglobulin treatment. Patients will be authorised for a single dose or period of continuing treatment according to the Criteria.
2016-immunoglobulin-governance-national-policy-updatev4.docx